Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T16:03:37.986Z.
Calculation as of: 2026-10-06T16:03:37.986Z.
Quote observation: 2026-10-06T16:00:04.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fc2e94c8beea8e322b310e9b25a1b89028fd55b2fc6a2790cf1d230843e32158
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$38.96M
EV/EBIT Ratio
74.65x
TTM Avg
60.42x
3Y Avg
123.40x
5Y Avg
130.57x
Market Cap
$40.28M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Incannex Healthcare Limited (IXHL) | $38.00M | N/A | N/A | N/A | N/A |
| Harvard Bioscience, Inc. (HBIO)vs › | $38.96M | 74.65x | 60.42x | 123.40x | 130.57x |
| Edesa Biotech, Inc. (EDSA)vs › | $36.99M | N/A | N/A | N/A | N/A |
| QT Imaging Holdings, Inc. (QTI)vs › | $36.63M | N/A | N/A | N/A | N/A |
| Nephros, Inc. (NEPH)vs › | $39.63M | 21.80x | 36.10x | 319.62x | 319.62x |
| Elicio Therapeutics, Inc. (ELTX)vs › | $36.23M | N/A | N/A | N/A | N/A |
| DocGo Inc. (DCGO)vs › | $35.76M | N/A | 8.66x | 44.05x | 43.98x |
| Metagenomi, Inc. Common Stock (MGX)vs › | $40.28M | N/A | N/A | N/A | N/A |
| BriaCell Therapeutics Corp. (BCTX)vs › | $35.62M | N/A | N/A | N/A | N/A |
| Elutia Inc (ELUT)vs › | $35.42M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
